This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Penile carcinoma

Authoring team

The majority (95%) are a squamous cell carcinoma. They are rare in the UK but are frequent in the Far East and African countries. The tumour arises from the inner surface of the foreskin or glans penis in the region of the coronal sulcus i.e. between glans and prepuce. It spreads locally and frequently invades the distal urethra. The inguinal lymph nodes are commonly involved, often bilaterally, but blood borne spread is rare and late.

The condition may start as leucoplakia on the glans or may develop from an in-situ carcinoma - erythroplasia of Queryat (1)

Carcinoma is rare in the circumcised (1).

1 in 493 UK males will be diagnosed with penile cancer in their lifetime (2)

  • are around 640 new penile cancer cases in the UK every year, that's nearly 2 every day (2013-2015)
  • in males in the UK, penile cancer is not among the 20 most common cancers, with around 640 new cases in 2015
  • penile cancer accounts for less than 1% of all new cancer cases in males in the UK (2015)
  • incidence rates for penile cancer in the UK are highest in males aged 90+ (2013-2015). Since the early 1990s, penile cancer incidence rates have increased by almost a quarter (23%) in males in the UK
  • over the last decade, penile cancer incidence rates have increased by around a fifth (21%) in males in the UK. Most penis cancers occur in the glans penis

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.